Skip to main content

Q and A with world-renowned malaria research expert Dr. Chris Plowe

May 20, 2015

Dr. Christopher Plowe

Dr. Christopher Plowe is a world-renowned expert in malaria research. For more than 25 years, he has drawn support from NIH, including a long-standing Fogarty training grant to develop malaria research capacity in Mali. He founded and directs the University of Maryland School of Medicine's new Institute for Global Health, which will incorporate the school's Center for Malaria Research and Center for Vaccine Development. He has received a Doris Duke Distinguished Clinical Scientist Award and the Bailey K. Ashford Medal for distinguished work in tropical medicine. He is also a Howard Hughes Medical Institute investigator, focused on accelerating the translation of genomics into health interventions, and is the 2015 president of the American Society of Tropical Medicine and Hygiene.

What are the most pressing questions in malaria treatment and diagnostics?

For one, what to do when we have untreatable malaria. In western Cambodia, there's malaria that's resistant not only to the artemisinin drugs but to some partner drugs. While we're still able to use a different artemisinin-based combination therapy, we're pretty close to having untreatable malaria. And so we desperately need new drugs with different mechanisms of action and of resistance. For another, we badly need ultrasensitive and robust tests to diagnose low levels of malaria infection in rural Africa and Asia. There's perhaps much more malaria than we imagined in asymptomatic people and if we want to eliminate the disease, we must eliminate all malaria parasites, not just those causing fever at a given time. We must also diagnose and treat fevers caused by other pathogens, because as malaria gets less common, more people coming to a clinic with fever will have something other than malaria.

Why is resistance not a problem in Africa and what is the risk?

We do see some of the mutations in a resistance gene for artemisinin resistance at low frequencies in Africa. We know now that they've been occurring for at least 15 years in Mali, for example. So these mutations appeared before artemisinin was ever used in that part of the world, and they kind of pop up here and there but they don't ever really become very frequent. We suspect that the reason for this is that the resistant parasites have a fitness disadvantage. For instance, Africa has a lot of people with partial immunity that allows them to be infected but not have any symptoms and therefore not be taking any drugs, then when there's not so much drug around the resistant parasites will be outcompeted by their more fit sensitive cousins.

What are about treatment for particularly difficult cases, such as cerebral malaria?

We have pretty good drugs to treat cerebral malaria, treat malaria in pregnancy - the same drugs by and large that we use to treat uncomplicated malaria. What we need in cerebral malaria in particular is other adjunctive treatments. So, for example, Terrie Taylor [Dr. Terrie Ellen Taylor, NIH grantee including Fogarty], an NIH-funded scientist working in Malawi, has come up with some very interesting evidence of the mechanisms of how kids die from cerebral malaria, and it may be that just ventilating children when they become extremely ill with cerebral malaria could get them through that danger period and allow the antimalarial drugs time to act. So some of the non-pharmacological treatments may be promising.

What hope comes from genomics?

We and others are beginning to harness the power of the genomic revolution in ways that are directly relevant to malaria elimination. We've done genome-wide association studies that have helped pinpoint the molecular marker of artemisinin resistance that has now led to tools for surveillance. And we're working on approaches to analyze the genomes of parasites in vaccine trials, with the hope we can better understand the need for multi-strain vaccines to protect against genetically diverse parasites and potentially identify new targets for malaria vaccines by finding out which genes in the parasite are under selection by vaccine-induced immunity.

Until recently, the strategy against drug resistant malaria has been to try to contain it and prevent it from spreading. But some of the genomic studies show that when you see the same resistance mutation in two places, there are some instances of resistance spreading, for example, between Cambodia and southern Vietnam. But there are other cases of completely independent emergence of the same mutations, for example, in Myanmar. If there's resistance popping up independently, you can't expect to put up a firewall and block it; you have to eliminate malaria from the entire region. The WHO is now shifting their recommendation from a containment strategy to total elimination of malaria in the greater Mekong subregion. It will take a lot of resources, coordination and collaboration across borders and across sectors. A big part of malaria elimination is going to be political will, where we're working with many partners in Myanmar to try to build and sustain political will for a national malaria elimination campaign as part of a regional malaria elimination campaign.

What is the outlook for a malaria vaccine?

We'll have a licensed malaria vaccine relatively soon. It has significant protective efficacy, but not nearly as high as we would like, so one approach is to improve its immunogenicity and/or add additional malaria antigens to make an expanded multistage, multicomponent vaccine. The other approach is a whole organism vaccine. Early clinical trials in the U.S. giving people a whole organism vaccine and then challenging them with the same strain of parasite have shown up to 100 percent protection. Now the big question is, will this work in the field where we have many different genetic variances of parasite? Those studies are happening now in Mali and being planned in Burkina Faso.

If and when can malaria be eradicated worldwide?

One of the more optimistic predictions I have heard is from Bill Gates at the American Society of Tropical Medicine and Hygiene meeting a few months ago. He said he would like to see malaria eradicated in his lifetime. The feeling is that this is possible, if we have very effective new tools, for instance if we have a highly efficacious malaria vaccine that gives long-lasting protection after a single immunization. Because we have to struggle not only with the malaria parasite but with the social and economic and political situations in which malaria parasites thrive, it will be very difficult to achieve global malaria eradication with our current tools - we really need some new drugs, new vaccines, new approaches.

What is the state of capacity in endemic areas?

Malaria research capacity is very strong in some lower-and middle-income countries, Mali being a great example of that. Over 25 years, the Malaria Research and Training Center there has become one of the world's leading research institutions bar none. Their investigators are independently competing for grants from NIH and the European Union and it's a very strong program. We'd like to see that happen in other countries including, for example, in Myanmar, where there's a very strong culture of research and very good lab capacity. For highly sensitive tests to diagnose very low levels of malaria, molecular test and for genotyping the resistance genes, we don't think that we should be shipping samples off to the United States or United Kingdom for analyses. We are working very hard with our partners in Myanmar to establish the ability to do these kinds of research assays and to develop new research tools in the country with their scientists in their labs.

If we want to eliminate malaria everywhere, eventually eradicate it, we must have stronger research capacity in many more places. We have to make the case to the funders as well as local governments that we'll eliminate malaria only by building up research capacity in the malaria endemic areas. Part of that has to do with the science and the need to have scientists engaged in the field who understand the important questions driving the research agenda. But another component involves generating and sustaining political will. If scientists in countries where malaria elimination is moving forward simply collect samples and send them off to the U.S. or Europe, they and their leaders will be a lot less motivated to sustain the support for malaria elimination than if they've built up their own capacity, if they're the ones collecting and analyzing and interpreting the evidence for where, when and how to deploy malaria elimination interventions. That's what it's going to take in the long run.


Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Monday, July 18, 2022

    New Genomic Research Shows Why Testing Malaria Vaccines in the Clinic is as Rigorous as Natural Exposure in the Field

    Malaria is the deadliest mosquito-borne parasitic infection of humans. In 2021, after a century of research, the World Health Organization (WHO) approved the world’s first malaria vaccine. That vaccine reduces the incidence of malaria infections in young children aged 5-17 months by only 30 percent, meaning that it remains critical to continue developing and testing more effective vaccines.

    Tuesday, November 02, 2021

    Unexpected Antibody Type Found in People with Malaria Infections

    Malaria, a pathogen transmitted into blood by mosquitoes in tropical climates, is typically thought of as a blood and liver infection. However, in a newly published study, researchers at the University of Maryland School of Medicine (UMSOM) have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as the lungs, intestines, or vagina — in study participants with malaria.

    Sunday, October 28, 2018

    American Society of Tropical Medicine & Hygiene Awards Dr. Miriam Laufer the LePrince Medal for Malaria Research

    Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director for Malaria Research at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD), was awarded the Joseph Augustin LePrince Medal by the American Society of Tropical Medicine and Hygiene (ASTMH).

    Thursday, May 04, 2017

    UM School of Medicine Researchers Receive $9 Million Grant for Malaria Research

    The University of Maryland School of Medicine has been awarded an International Center of Excellence for Malaria Research (ICEMR) grant by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), one of seven ICEMRs awarded worldwide. With funding of more than $9 million over seven years, the grant will be used to research and develop new tools to help eliminate drug-resistant malaria in Myanmar and neighboring countries in Southeast Asia.

    Friday, February 24, 2017

    Experimental Malaria Vaccine Provides Durable Protection Against Multiple Strains in NIH Clinical Trial

    An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published this week in the Proceedings of the National Academy of Sciences (PNAS). The research was conducted by scientists at the University of Maryland School of Medicine and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

    Thursday, September 22, 2016

    University of Maryland School of Medicine Holds Inaugural Global Health Summit

    The Institute for Global Health (IGH) at the University of Maryland School of Medicine (UM SOM) will hold its first Global Health Summit on September 26. The event, which will take place from noon to 6 p.m. in the SMC Campus Center at 621 W. Lombard Street, will seek to foster collaboration among scientists and promote new and innovative global health research at UM SOM, as well as at other schools at the University of Maryland, Baltimore (UMB). Faculty and staff from UM SOM, as well as other schools are welcome at the event.

    Wednesday, July 06, 2016

    UMSOM Begins Malaria Vaccine Trial in Burkina Faso

    Malaria is one of the world’s deadliest diseases: it infects hundreds of millions of people every year, and kills about half a million, most of them under five years of age.

    Friday, June 24, 2016

    Investiture Celebrates the Courage and Passion of Two University Warriors

    In a packed Westminster Hall, with one of the largest audiences to date for any investiture ceremony, Christopher Plowe, MD, MPH, was named the Frank M. Calia, MD Professor of Medicine.

    Tuesday, April 12, 2016

    UM SOM Researcher Dr. Kathleen Neuzil Honored by Vanderbilt University School of Medicine

    The Vanderbilt University School of Medicine (VUSM) has announced that Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development at the University of Maryland School of Medicine (UM SOM), has received the 2016 Vanderbilt University School of Medicine Distinguished Alumni Award.

    Tuesday, August 04, 2015

    New Institute for Global Health at University of Maryland School of Medicine Helps Organize Historic Summit to Address Malaria Epidemic in Myanmar

    The University of Maryland School of Medicine’s Institute for Global Health (IGH), recently established under the direction of Christopher Plowe, MD, MPH, Professor of Medicine, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced that it will help bring together a diverse array of opposing factions from Myanmar as part of an unprecedented unified effort to eliminate the country’s most fatal disease: malaria.